Allianz Asset Management’s Albany Molecular Research Inc AMRI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q3 | – | Sell |
-442,716
| Closed | -$9.61M | – | 2743 |
|
|
2017
Q2 | $9.61M | Buy |
442,716
+170,385
| +63% | +$3.09M | 0.01% | 1323 |
|
|
2017
Q1 | $3.82M | Sell |
272,331
-34,940
| -11% | -$572K | ﹤0.01% | 1740 |
|
|
2016
Q4 | $5.76M | Sell |
307,271
-38,931
| -11% | -$662K | 0.01% | 1599 |
|
|
2016
Q3 | $5.71M | Sell |
346,202
-39,149
| -10% | -$580K | 0.01% | 1569 |
|
|
2016
Q2 | $5.18M | Sell |
385,351
-10,045
| -3% | -$147K | 0.01% | 1498 |
|
|
2016
Q1 | $6.05M | Sell |
395,396
-441,879
| -53% | -$6.93M | 0.01% | 1369 |
|
|
2015
Q4 | $16.6M | Buy |
837,275
+76,469
| +10% | +$1.45M | 0.02% | 836 |
|
|
2015
Q3 | $13.3M | Buy |
760,806
+13,126
| +2% | +$267K | 0.02% | 867 |
|
|
2015
Q2 | $15.1M | Sell |
747,680
-44,593
| -6% | -$861K | 0.02% | 919 |
|
|
2015
Q1 | $13.9M | Sell |
792,273
-122,823
| -13% | -$2.09M | 0.02% | 821 |
|
|
2014
Q4 | $14.9M | Buy |
915,096
+2,819
| +0.3% | +$51.7K | 0.02% | 816 |
|
|
2014
Q3 | $20.1M | Buy |
912,277
+99,153
| +12% | +$2.03M | 0.02% | 637 |
|
|
2014
Q2 | $16.4M | Sell |
813,124
-70,280
| -8% | -$1.19M | 0.02% | 620 |
|
|
2014
Q1 | $16.4M | Buy |
883,404
+76,806
| +10% | +$1.06M | 0.02% | 606 |
|
|
2013
Q4 | $8.13M | Buy |
806,598
+6,788
| +0.8% | +$82K | 0.01% | 807 |
|
|
2013
Q3 | $10.3M | Sell |
799,810
-22,475
| -3% | -$276K | 0.01% | 660 |
|
|
2013
Q2 | $9.76M | Buy |
+822,285
| New | +$8.91M | 0.01% | 647 |
|
Other funds holding AMRI
Allianz Asset Management's AMRI Position: Q3 2017 in Review
Allianz Asset Management sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 442,716 shares — an estimated $9.61M sold.
Allianz Asset Management first reported a position in AMRI in Q2 2013 and held it in 17 quarters. The position peaked at $20.1M in Q3 2014. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.
- Allianz Asset Management reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
- Allianz Asset Management sold 442,716 Albany Molecular Research Inc shares in Q3 2017, an estimated $9.61M.
- Allianz Asset Management first reported a position in Albany Molecular Research Inc in Q2 2013 and held it in 17 quarters.
- Allianz Asset Management's Albany Molecular Research Inc position peaked at $20.1M in Q3 2014.
- 2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.
Based on Allianz Asset Management's 13F filing for Q3 2017, filed 13 Nov 2017.